Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory, Boston University Medical Center, 48288-48289 [E7-16645]
Download as PDF
<![CDATA[
48288
Federal Register / Vol. 72, No. 163 / Thursday, August 23, 2007 / Notices
ebenthall on PRODPC61 with NOTICES
measurements of a sequence common to
several targets.
The method’s software design allows
for large (>10,000) target sets and large
probe set sizes (2->1,000,000). While
current selection criteria involve a time
consuming iterative and manual
process, the present invention allows for
the identification of a quantitatively
optimized probe set which balances
probe performance criteria and
simultaneously optimizes the sensitivity
and specificity of the assay for a given
set of targets.
Applications: The invention has
applications in the design of various
important assays, such as those based
on microarrays, multiplexed PCR and
SPR, targeted protein fragment
detection, or any sequence-specific
binding and detection. It has application
where the number of probes to be used
in an assay is too large for manual
design and review.
Inventors: Eric Billings and Kevin E.
Brown (NHLBI).
Patent Status: U.S. Provisional
Application No. 60/871,447 filed 21 Dec
2006, entitled ‘‘Probe Set Global
Optimization’’ (HHS Reference E–332–
2005/0–US–01).
Development Status: The technology
is ready to be applied and validated in
many different areas for research and
diagnostic purposes.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Cristina
Thalhammer-Reyero, Ph.D., M.B.A.;
301/435–4507; thalhamc@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute, Computational Biophysics
Laboratory is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, utilize or
commercialize a method for optimizing
sequence-based assays. Please contact
Dr. Eric Billings, at (301) 496–6520 or
via e-mail at billings@helix.nih.gov for
more information.
Dated: August 16, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–16644 Filed 8–22–07; 8:45 am]
BILLING CODE 4140–01–P
VerDate Aug<31>2005
15:04 Aug 22, 2007
Jkt 211001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Eye Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Eye Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Eye Council.
Date: September 27, 2007.
Closed: 8:30 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: National Institutes of Health, 5635
Fishers Lane, Terrace Level Conference
Center, Bethesda, MD 20982.
Open: 10:30 a.m. to Adjournment.
Agenda: Following opening remarks by the
Director, NEI there will be presentations by
the staff of the Institute and discussions
concerning Institute programs.
Place: National Institutes of Health, 5635
Fishers Lane, Terrace Level Conference
Center, Bethesda, MD 20892.
Contact Person: Lore Anne McNicol, PhD,
Director, Division of Extramural Research,
National Eye Institute, National Institutes of
Health, Bethesda, MD 20892, (301) 451–2020.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institutes’s/Center’s home page: https://
www.nei.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Dated: August 14, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 07–4100 Filed 8–21–07; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory, Boston University Medical
Center
Availability of Supplementary
Risk Assessments and Site Suitability
Analyses for the National Emerging
Infectious Disease Laboratory, Boston
University Medical Center; notice of
hearing.
ACTION:
SUMMARY: The National Institutes of
Health (NIH) has placed in the docket
for public review and comment the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory, Boston University Medical
Center, which address additional
concerns of the local community
regarding possible impacts of the
National Emerging Infectious Diseases
Laboratory, Boston University Medical
Center. The purpose of the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory was alternative site analysis
and risk assessment that investigated
potential infectious disease threats that
may be posed to the public should an
exotic infectious agent be released into
the community through an infected
laboratory worker, laboratory accident,
or other mishap.
DATES: Comments on the
Supplementary Risk Assessments and
Site Suitability Analyses for the
National Emerging Infectious Disease
Laboratory must be received by
Monday, November 12th. A public
hearing will be held on Thursday,
September 20, 2007, from 7–9 p.m. at
Faneuil Hall, Dock Square, Boston, MA
02109.
ADDRESSES: Comments should be sent to
Valerie Nottingham, Division of
Environmental Protection, National
Institutes of Health, 9000 Rockville
Pike, Building 13, Room 2S11,
Bethesda, MD 20892, MSC 5746. E-mail
comments should be sent to
nihnepa@mail.nih.gov. Comments sent
by e-mail must be received by 11:59
E:\FR\FM\23AUN1.SGM
23AUN1
ebenthall on PRODPC61 with NOTICES
Federal Register / Vol. 72, No. 163 / Thursday, August 23, 2007 / Notices
p.m. on the last day of the comment
period, Monday, November 12, 2007.
FOR FURTHER INFORMATION CONTACT:
Valerie Nottingham, Division of
Environmental Protection, National
Institutes of Health, 9000 Rockville
Pike, Building 13, Room 2S11,
Bethesda, MD 20892, MSC 5746,
telephone number 301–496–7775, Email address: nihnepa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
National Institutes of Health awarded a
construction grant to Boston University
to partly fund the design and
construction of one of two National
Biocontainment Laboratories (NBLs).
These advanced biomedical research
laboratories are essential to the civilian
biodefense initiative providing critically
needed Biosafety Levels 2, 3, and 4
research space. The basic and
translational research to be conducted
in these laboratories over the next 20
years will result in development of new
rapid diagnostic assays, vaccines and
therapeutics for protection of the
American public against intentional
misuse or release of harmful biological
agents or toxins and emerging and reemerging infectious diseases such as
H5N1 highly pathogenic avian influenza
and the SARS coronavirus.
The NIH completed and published a
final Environmental Impact Statement
(EIS) and published a Record of
Decision as required for major federal
actions under the National
Environmental Policy Act (NEPA).
Construction of the National Emerging
Infectious Diseases Laboratory (NEIDL)
began at the BioSquare II Research Park
on Albany Street, Boston, Massachusetts
adjacent to the Boston University
Medical Center (BUMC).
During the preparation of the EIS, the
NIH conducted a thorough review of the
possible impacts of the NBL on the
public and the environment. That
review demonstrated that the
construction and operation of the NBL
was not a risk to the community in
which the laboratory was sited or
surrounding communities. In response
to additional and lingering concerns
raised by some members of the
community, the NIH has performed
additional reviews of the potential
impacts of the NBL. These reviews
included additional ‘‘hard look’’
alternative site analyses and risk
assessments investigating potential
infectious disease threats that may be
posed to the public should an exotic
infectious agent be released into the
community through an infected
laboratory worker, laboratory accident
or other mishap. Additionally, the risk
assessments specifically addressed an
VerDate Aug<31>2005
15:04 Aug 22, 2007
Jkt 211001
on-going community concern that an
Environmental Justice community near
the proposed NEIDL site in Boston
would be disproportionately impacted
should a release occur.
Availability of Copies and Electronic
Access
Copies of the Supplementary Risk
Assessments and Site Suitability
Analyses for the National Emerging
Infectious Disease Laboratory, Boston
University Medical Center may be
obtained at no cost by calling 301–496–
7775, or by emailing requests to
nihnepa@mail.nih.gov. Documents are
available in alternate formats upon
request. Persons who want a publication
in an alternate format should specify the
type of format. The document will also
be available on the NIH Web site
https://www.nems.nih.gov/aspects/
nat_resources/programs/nepa.cfm.
Dated: August 15, 2007.
Daniel G. Wheeland,
Director, Office of Research Facilities
Development and Operations, NIH.
[FR Doc. E7–16645 Filed 8–22–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Information Collection Authority Under
Homeland Security Acquisition
Regulation (HSAR)
Office of Chief Procurement
Officer, Acquisition Policy and
Legislation Office, DHS.
ACTION: Submission for OMB review;
comment request.
AGENCY:
SUMMARY: The Department of Homeland
Security, Office of the Chief
Procurement Officer, Acquisition Policy
and Legislation Office, has submitted
the following information collection
request (ICR) to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995 (Pub. L. 104–13, 44 U.S.C. Chapter
35). The Office of the Chief Procurement
Officer is soliciting comments
concerning an extension to an existing
collection, Information collection
authority under Homeland Security
Acquisition Regulation (HSAR).
DATES: Comments are encouraged and
will be accepted until October 22, 2007.
This process is conducted in accordance
with 5 CFR 1320.1
ADDRESSES: Comments and questions
about this Information Collection
Request should be forwarded to the
Acquisition Policy and Legislation
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
48289
Office, Attn: Kathy Strouss for the
Department of Homeland Security,
Office of the Chief Procurement Officer,
Room 3114, Washington, DC 20528.
FOR FURTHER INFORMATION CONTACT:
Kathy Strouss, 202–447–5300 (this is
not a toll free number).
SUPPLEMENTARY INFORMATION: The
Department of Homeland Security
(DHS), Office of the Chief Procurement
Officer requires a renewal request and a
revision of an existing OMB Control
number for four forms in the HSAR 48
CFR Chapter 30. This notice provides a
request for renewal of the designated
OMB Control Number 1600–0002
previously granted in September 2004
on the following four forms: DHS Form
0700–01, DHS Form 0700–02, DHS
Form 0700–03, and DHS Form 0700–04.
These four forms will be used by
contractors and/or contract employees
during contract administration. A fifth
form, DHS Form 0700–05, which was
included with initial clearance and
approval for this OMB control number
1600–0002 in September 2004, is
obsolete due to recent changes in the
Federal Acquisition Regulation (FAR)
48 CFR Chapter 2. The change to FAR
Part 45 was effective June 14, 2007 and
removed previously existing annual
contractor reporting requirements. The
DHS Form 0700–05 supported the
collection of the annual contractor
report. A HSAR change will include
designation of the DHS Form 0700–05,
Contractor Report of Government
Property as obsolete. No extension of
the collection is requested for this form.
DHS Form 0700–04, Employee Claim for
Wage Restitution, requires an
amendment to reflect a name change.
The office designated for receipt of the
claim currently appears as ‘‘The General
Accounting Office’’ but the name has
changed to ‘‘The Government
Accountability Office’’. No other
amendments to the DHS HSAR forms
are anticipated. The Office of
Management and Budget is particularly
interested in comments regarding the
following:
1. Whether the collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information shall have practical utility;
2. The accuracy of the agency’s
estimate of the burden of the collection
of information;
3. Ways to enhance the quality,
utility, and clarity of the information to
collected;
4. Ways to minimize the information
collection burden.
5. Estimates of capital or start-up costs
and costs of operation, maintenance,
E:\FR\FM\23AUN1.SGM
23AUN1
]]>Agencies
[Federal Register Volume 72, Number 163 (Thursday, August 23, 2007)]
[Notices]
[Pages 48288-48289]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16645]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Supplementary Risk Assessments and Site Suitability Analyses for
the National Emerging Infectious Disease Laboratory, Boston University
Medical Center
ACTION: Availability of Supplementary Risk Assessments and Site
Suitability Analyses for the National Emerging Infectious Disease
Laboratory, Boston University Medical Center; notice of hearing.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH) has placed in the
docket for public review and comment the Supplementary Risk Assessments
and Site Suitability Analyses for the National Emerging Infectious
Disease Laboratory, Boston University Medical Center, which address
additional concerns of the local community regarding possible impacts
of the National Emerging Infectious Diseases Laboratory, Boston
University Medical Center. The purpose of the Supplementary Risk
Assessments and Site Suitability Analyses for the National Emerging
Infectious Disease Laboratory was alternative site analysis and risk
assessment that investigated potential infectious disease threats that
may be posed to the public should an exotic infectious agent be
released into the community through an infected laboratory worker,
laboratory accident, or other mishap.
DATES: Comments on the Supplementary Risk Assessments and Site
Suitability Analyses for the National Emerging Infectious Disease
Laboratory must be received by Monday, November 12th. A public hearing
will be held on Thursday, September 20, 2007, from 7-9 p.m. at Faneuil
Hall, Dock Square, Boston, MA 02109.
ADDRESSES: Comments should be sent to Valerie Nottingham, Division of
Environmental Protection, National Institutes of Health, 9000 Rockville
Pike, Building 13, Room 2S11, Bethesda, MD 20892, MSC 5746. E-mail
comments should be sent to nihnepa@mail.nih.gov. Comments sent by e-
mail must be received by 11:59
[[Page 48289]]
p.m. on the last day of the comment period, Monday, November 12, 2007.
FOR FURTHER INFORMATION CONTACT: Valerie Nottingham, Division of
Environmental Protection, National Institutes of Health, 9000 Rockville
Pike, Building 13, Room 2S11, Bethesda, MD 20892, MSC 5746, telephone
number 301-496-7775, E-mail address: nihnepa@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The National Institutes of Health awarded a
construction grant to Boston University to partly fund the design and
construction of one of two National Biocontainment Laboratories (NBLs).
These advanced biomedical research laboratories are essential to the
civilian biodefense initiative providing critically needed Biosafety
Levels 2, 3, and 4 research space. The basic and translational research
to be conducted in these laboratories over the next 20 years will
result in development of new rapid diagnostic assays, vaccines and
therapeutics for protection of the American public against intentional
misuse or release of harmful biological agents or toxins and emerging
and re-emerging infectious diseases such as H5N1 highly pathogenic
avian influenza and the SARS coronavirus.
The NIH completed and published a final Environmental Impact
Statement (EIS) and published a Record of Decision as required for
major federal actions under the National Environmental Policy Act
(NEPA). Construction of the National Emerging Infectious Diseases
Laboratory (NEIDL) began at the BioSquare II Research Park on Albany
Street, Boston, Massachusetts adjacent to the Boston University Medical
Center (BUMC).
During the preparation of the EIS, the NIH conducted a thorough
review of the possible impacts of the NBL on the public and the
environment. That review demonstrated that the construction and
operation of the NBL was not a risk to the community in which the
laboratory was sited or surrounding communities. In response to
additional and lingering concerns raised by some members of the
community, the NIH has performed additional reviews of the potential
impacts of the NBL. These reviews included additional ``hard look''
alternative site analyses and risk assessments investigating potential
infectious disease threats that may be posed to the public should an
exotic infectious agent be released into the community through an
infected laboratory worker, laboratory accident or other mishap.
Additionally, the risk assessments specifically addressed an on-going
community concern that an Environmental Justice community near the
proposed NEIDL site in Boston would be disproportionately impacted
should a release occur.
Availability of Copies and Electronic Access
Copies of the Supplementary Risk Assessments and Site Suitability
Analyses for the National Emerging Infectious Disease Laboratory,
Boston University Medical Center may be obtained at no cost by calling
301-496-7775, or by emailing requests to nihnepa@mail.nih.gov.
Documents are available in alternate formats upon request. Persons who
want a publication in an alternate format should specify the type of
format. The document will also be available on the NIH Web site http:/
/www.nems.nih.gov/aspects/nat_resources/programs/nepa.cfm.
Dated: August 15, 2007.
Daniel G. Wheeland,
Director, Office of Research Facilities Development and Operations,
NIH.
[FR Doc. E7-16645 Filed 8-22-07; 8:45 am]
BILLING CODE 4140-01-P
